Histamine in diabetes: is it time to reconsider?

Alessandro Pini\textsuperscript{a}, Ilona Obara\textsuperscript{b}, Emma Battell\textsuperscript{c}, Paul L Chazot\textsuperscript{c}, Arianna Carolina Rosa\textsuperscript{c,d}

\textsuperscript{a}Department of Clinical and Experimental Medicine, University of Florence, Viale Pieraccini 6 - 50139, Florence, Italy, apini@unito.it; \textsuperscript{b}School of Medicine, Pharmacy and Health, Durham University, Stockton-on-Tees TS17 6BH, United Kingdom, ilona.obara@durham.ac.uk; \textsuperscript{c}School of Biological and Biomedical Science, Durham University, Durham DH13LE, UK, emma.battell@durham.ac.uk and paul.chazot@durham.ac.uk; \textsuperscript{d}Department of Scienza e Tecnologia del Farmaco, University of Turin, Via P. Giuria 9 - 10125, Turin, Italy, acrosa@unito.it

Corresponding author:

Alessandro Pini,

Department of Clinical and Experimental Medicine, University of Florence,

Viale Pieraccini 6 - 50139, Florence, Italy

Phone: +390552758155

e-mail: apini@unifi.it
Abstract

The first studies of histamine and diabetes date back to the 1950s. Since that time the involvement of histamine in diabetes was related to its well known vasoactive properties and permeability leakage effects. In particular, the first evidence for a correlation between histamine and diabetes arose in 1989 when an increase in plasma and leucocyte histamine content was observed. Limited independent evidence followed in the subsequent two decades, focusing on both histamine glyceamic control and macro- and microvascular complications of diabetes. However, recent observations have sparked the question whether it is time to reconsider the functional contribution of histamine in diabetes. We reveal an interesting upsurge in the field which provides scope for new insights into the role of histamine in diabetes.

Keywords: histamine, histamine receptor, diabetes, nephropathy, retinopathy, neuropathy

Abbreviations:

ADP = action potential duration; AGEs = advanced glycation end-products; BM = basement membrane; BRB = blood-retinal barrier; CGRP = calcitonin gene related peptide; CKD = chronic kidney disease; DAO = diamine oxidase; DiO = diet-induced obesity; ESRD = end-stage renal disease; H1,4Rs = histamine H1,4Rs; HbA1 = glycated hemoglobin; HDC = histidine decarboxylase; STZ = streptozotocin; TGF-β = tissue growth factor-β; TCAs = tricyclic antidepressants; \( V_{max} \) = maximum rate of depolarization; VEGF = vascular endothelial growth factor; ZO-1 = zonula occludent-1
1 Introduction

Diabetes mellitus can be considered a family of chronic degenerative disorders associated with a hyperglycemic status caused by either the loss of insulin production due to the destruction of beta pancreatic cells, decreased insulin sensitivity, or both [1, 2]. In 2014, the global prevalence of 8.3% has been estimated and by the end of 2030 this value is expected to rise up to 55% [3], resulting in obvious devastating consequences for healthcare expenditure worldwide. All the antidiabetic drugs currently available, although effective in reducing the risk of acute complications, such as hypoglycemia and hyperglycemia [4], are not effective in reversing the progression of this chronic and degenerative disorder. Indeed, diabetic patients are still at a high risk to develop longstanding complications including cardiovascular disease, such as coronary artery disease, and microvascular diseases, including neuropathy, retinopathy and nephropathy. Therefore, a better understanding of the underlying pathophysiology should contribute to new effective therapeutic approaches. Among the different mediators proposed to contribute to the pathophysiology of diabetes, histamine involvement has always been controversial and considered almost marginal. However, several lines of evidence support the contribution of histamine to the diabetic milieu resulting from the persistent hyperglycemia. For instance, the advanced glycation end-products (AGEs) have been demonstrated to activate mast cells whose degranulation may contribute to a vicious cycle, ultimately resulting in a low-grade inflammation typical of chronic diseases such as diabetes [5]. Therefore, this review aims to revisit the concept of histamine in the pathophysiology of diabetes and, in particular, its complications.

2 Histamine and glycaemia

Histamine is involved in a wide variety of pathophysiological events mostly related to the inflammatory response through four receptors, namely H1-Rs. The first studies of histamine and diabetes date back to the 1950s. Since that time the involvement of histamine in diabetes was
related to its well-known vasoactive properties and permeability leakage effects correlated to microvascular complications. In particular, the first evidence for a correlation between histamine and diabetes came in 1989 through the work of Gill and colleagues when they reported an increase in plasma and leucocyte histamine content which was claimed to contribute to the underlying pathogenesis evoking endothelial permeability [6]. These findings were in keeping with in vivo studies of experimental diabetes suggestive of an increased histaminergic tone in diabetic rodents. Indeed, histamine was found to be increased in plasma, kidney, brain, lung, heart, pancreas and intestine [6, 7] of diabetic rats. Independent evidence also suggested a parallel imbalance of the anabolism and catabolism of this amine with an increased synthesis and a simultaneous decreased catabolism [8-11]. For instance, a significant drop in intestinal diamine oxidase (DAO) activity [7] as well as an increase of histidine decarboxylase (HDC) activity in various tissues [12] were observed, thus providing evidence for a nascent histamine pool. The very recent observation of a reduced prevalence of hyperglycemia in HDC−/− NOD mice (an animal model of spontaneous type 1 diabetes) in comparison with the wild-type counterpart [13] strongly lends weight to this original hypothesis.

More intriguingly, it has been reported that histamine plasma and aortic synthesis [10] in diabetic rats are reduced when insulin is administrated [14], thus strongly supporting the hypothesis for an interconnection between histamine and glycaemic status. This hypothesis is further strengthened by the study of Azevedo and colleagues (1990) reporting an increase of pancreatic islet histamine content in streptozotocin (STZ)-induced diabetes rats [15]. Interestingly, recent data suggest the involvement of the peripheral H3R in the insulin-histamine loop (Supplementary Figure 1). Indeed, Nakamura and colleagues (2014) provided the first evidence for a potential diabetogenic effect of the pancreatic H3R, through reporting the presence of functional histamine H3R in this tissue. In particular, it has been demonstrated that H3R activation in pancreatic beta cells by imetit (PubChem CID 3692) inhibits the insulin secretion associated with high glucose levels in MIN6 cells [16]. Moreover, the same authors reported H3R expression in pancreatic alpha cells, indicating that H3R
activation may reduce glucagon production by αTC1.6 cells in a non-hyperglycemic condition [17].

Notably, although the H₃R has been known to play a critical role in homeostatic regulatory functions, such as control of food intake and maintenance of body weight [18], its contribution to diabetes is controversial [18-24] and still far from being fully understood. Indeed, the H₃R inverse agonist clobenoprit (PubChem CID 2790) has been demonstrated to increase the hypothalamic histamine release and reduce the energy intake in normal and leptin-resistant mice with diet-induced obesity (DiO) [25]. So far, some newly synthesized H₃R antagonists have been specifically tested in diabetic animal models demonstrating an effectiveness in reducing non-fasting glucose levels by potentially blocking the increase of HbA₁ [26]. More interestingly, the strategy of an H₃R antagonism combined with a phenylsulfonylurea (well-known insulinotropic drugs) moiety has been explored [27]; although an effective prototype remains elusive. On the contrary, the activation of H₃Rs in mice has been reported to decrease food intake and increase energy expenditure. Chronic dosing with a H₃R agonist reduces body weight, fat mass, hyperleptinemia, and hyperinsulinemia in DiO mice [28]. Conversely, the protem H₃R agonist proxyfan (PubChem CID 6421522) in mice improves glucose excursion increasing plasma insulin levels without affecting plasma glucagon levels [29]. Furthermore, the mildly obese H₃R-deficient mice also demonstrate leptin and insulin resistance with impaired glucose tolerance [28]. Notably, the majority of these data were obtained before the clear demonstration of H₃R peripheral expression [16, 30-34]. In particular, the pancreatic localization of the H₃R raises the question of contradictory effects mediated by peripheral and central H₃R.

Conflicting data concerning the involvement of H₂R on glycaemia has also arisen. Its antagonism was reported to decrease [35], not affect [36, 37] and increase [38, 39] glucose levels. In comparison, the clinical experience with antipsychotic drugs generated clearer evidence for the involvement of the central H₁R in the development of a diabetic phenotype [40]. Consistently, it has been found that the intra-ventricle or –hypothalamic administration of an H₁R agonist induces satiety evoking an anti-obesity effect [41, 42]. Moreover, a strategy based on the contemporary H₁R
agonism and H₃R antagonism was demonstrated to have the potential to reduce obesity also in patients with comorbidities such as diabetes [43].

3 Histamine and diabetes complications

As mentioned above, despite the effectiveness of the different anti-diabetic strategies in controlling glycaemic levels, due to the glucose variability, patients are still exposed to a high risk of developing one or more of the longstanding and serious complications [4]. According to the definitions by the World Health Organization, the complications can be divided into macrovascular complications (including coronary artery disease, peripheral arterial disease and stroke) and microvascular complications (including diabetic nephropathy, neuropathy and retinopathy). Notably, for each new case of one given complication, a higher probability to display another one has been clearly documented [44].

Interestingly, a higher content of histamine in the anatomical districts involved in the diabetic longterm complications has been reported in different studies [6, 7]. Independently from the source of histamine within these districts, due to an activation of mast cells, a recruitment of basophils, an imbalance in the amine anabolism/catabolism or all three, the increased histaminergic tone is a common feature of the different complications and deserves to be further clarified. In particular, based on its vascular actions, histamine has been suggested to be a key triggering stimulus for the functional microangiopathy in diabetes mellitus, from retinopathy to nephropathy. However, its complete functional contribution to diabetes microvascular complications is yet to be elucidated.

3.1 Histamine and macrovascular complications

Cardiovascular diseases (CVD) are one of the leading cause of death in diabetics, with an increased rate of heart disease or stroke from two- to four-fold compared to non-diabetic patients [45]. Notably, histamine has been reported to regulate several cardiovascular and endothelial functions through concerted actions on both smooth muscle and endothelial cells. These actions result in
vasoconstriction or vasodilation based on histamine level, diameter and initial vessel tone, and
relative location within the coronary circulation [46]. Again the first evidence for histamine
involvement in diabetic macrovascular complications comes from the 1980s studies, when the
histamine metabolism in both aortic endothelial and subjacent smooth muscle cells of control and
diabetic rats was studied [47]. Despite such intriguing initial results, the hypothesis suggested was
not further developed, with sparse, indirect and almost contrasting data remaining in the literature.

The evidence for a role of histamine stems from mast cell activation during the coronary blood
vessel inflammation underling the atherogenesis process [48, 49], but also from its release from
activated platelets [50]. Indeed, the number of mast cells was found to be increased in the narrow
parts of blood vessels or at the site of plaque rupture in patients suffering from ischemic heart
diseases [51, 52]. Notably, histamine release was demonstrated to significantly increase in coronary
circulation during myocardial ischemia irrespective of the incidence of risk factors such as
hypertension, type 2 diabetes, or dyslipidaemias [53].

Among the different receptors, historically the macrovascular effects of histamine seems to be
mostly related to the H₁R and H₂R, but no specific studies were designed to investigate the whole
histamine receptor family and only one observation claims the ability of H₃R to regulate the
coronary vascular response [54]. H₁R has been reported to mediate the overexpression of the
adhesion molecules [55] and the activation of nitric oxide synthase [55-57] evoked by histamine in
vascular endothelial cells. H₂R has been demonstrated to cause coronary dilation in both an
endothelium independent [56] and dependent [54] manner.

Apart from atherosclerosis, patients with diabetes mellitus also exhibit QT (QTc) interval
prolongation and increased QTc dispersion. Interestingly, HDC⁺⁻ mice with aging showed a
decrease in maximum rate of depolarization (Vₘₐₓ) and action potential duration (ADP)₉₀
prolongation comparable to those observed in the wild-type counterpart following diabetes
induction by STZ administration [58]. This observation is still far from being conclusive, but it is in
keeping with the suggested arrhythmogenic potential of histamine [59, 60]. Although no specific receptor involvement have been described, histamine has been reported to induce Purkinje-fibers depolarization drive to ventricular tachycardia [61]. In mastocytosis patients, when a massive mast cells recruitment and degranulation occur, cardiac arrest has been observed [62]. Moreover, atrial fibrillation was described consequently to anaphylaxis reaction to venom and pollen immunotherapy in patients with established hyperhistaminemia [63]. Finally, a recent study pointing at a connection between histamine and diabetes macrovascular complications concluded that manipulation of cardiac mast cell function with nedocromil (PubChem CID 50294), a mast cell stabilizer, is sufficient to attenuate cardiomyopathy stimulated by diabetes [64].

Collectively, in the literature, there are not enough data to support any conclusive dissertation on the role of histamine in the development/maintenance of the macrovascular complication of diabetes, with the majority of its effects ascribable to its general anti-inflammatory properties.

3.2 Histamine and microvascular complications

The vasoactive properties of histamine led to the hypothesis advocating its contribution to the development and maintenance of diabetes-related microvascular complications. As discussed above, the role of the amine was investigated in the different end-organ(s).

3.2.1 Diabetic neuropathy

Diabetic neuropathy is an heterogeneous family of nerve disorders resulting in improper locomotor and visceral organ dysfunctions at the level of peripheral, central, and visceral sensorimotor and motor nerves [65]. According to this definition we can recognize peripheral, autonomic, proximal, or focal neuropathy. Among these different neuropathies the peripheral subtype is the most common. As a consequence of the peripheral nerve degeneration, triggered by persistent hyperglycaemia, and according to the affected nerves, diabetes patients suffer from pain, weakness, and eventual loss of sensation in addition to severe chronic pain syndromes.
The wheal response to intradermal application of histamine in diabetic patients have been assessed since 1930 [66], but its involvement in pain transmission was clearly recognized only by Schwartz and collaborators in 1991. So far many strands of evidence have pointed to histaminergic neurotransmission as an important factor in the control of pain [67-70]. Indeed, diabetic patients have been described to be less responsive to histamine as well as other neurogenic inflammation mediators such as substance P. In addition, a bidirectional relationship between different neurotransmitters and histamine exists [71]. The mRNA of H₃R has been detected in many substance P positive neurons [72] and histamine has been shown to mediate the release of substance P and glutamate [73]. Also, the expression of H₃R and/or H₄R within calcitonin gene related peptide (CGRP) positive neurons [72] was determined. CGRP and histamine can establish a vicious circle inducing one another [70, 74, 75].

Although histamine has been reported to modulate nociception through all four types of its receptor, H₁R [69, 76-78], H₂R [76, 78, 79], H₃R [78, 79] and H₄R [80-85], in 2014 the H₃R antagonists were reported as very promising for neuropathic pain [86]. However, only one study was designed to evaluate the antinociceptive effect of the H₃R in a diabetic model. This respective study showed that the selective agonist immepip (PubChem CID 3035842) reversed formalin-induced hyperalgesia in both phases of the formalin test [87]. This effect could be associated with both H₃R peripheral activation, resulting in a reduction in inflammatory peptides release, and H₃R central activation, leading to the inhibition of pain transmission [88-92]. Consistent with this theory, immepip (PubChem CID 3035842) was found to inhibit mechanical, not thermal sensitivity in rats, but was shown to affect neither mechanical nor thermal sensitivity in mice [93]. Moreover, the role of H₃R receptor in nociception is still controversial, with different antagonists, including GSK189254 (PubChem CID 9798547), GSK334429 (PubChem CID 11452311) and ABT-239 (PubChem CID 9818903), demonstrated to be effective in reducing the sensitivity to mechanical stimuli [94] or in relief from surgically- and virally-induced neuropathic pain as well as inflammatory pain [82, 95, 96], respectively. The discrepancy emerging from the above described
literature can be specifically explained by the observation that the H₃R receptor is expressed both as an autoreceptor and heteroreceptor which inhibits the release of histamine [97] and other neurotransmitters, respectively, including acetylcholine, noradrenaline, dopamine and serotonin [98-102].

Notably, histamine has also been shown to play a role in autonomic neuropathy. Indeed, the deranged autonomic function of the airways in diabetic patients with autonomic neuropathy has been demonstrated to elicit an exaggerated response to histamine-induced bronchoconstriction [103]. A direct stimulation of bronchial smooth muscle contraction combined with vagal-mediated reflexes after stimulation of rapidly adapting irritant receptors and C-fibers has been argued to be the mechanism underlying the histamine-induce bronchoconstriction, while bronchomotor tone is mainly controlled by the parasympathetic nervous system. Therefore, the exaggerated response to histamine in diabetic patients could be due to the widespread autonomic damage to the respiratory parasympathetic and sympathetic pathways (including non-adrenergic non-cholinergic pathways influencing airway tone) and/or denervation hypersensitivity [104-111]. However, despite the above observations the role of histamine in autonomic neuropathy is still far from clear.

### 3.2.2 Diabetic retinopathy

Diabetic retinopathy is still one of the major worldwide cause of blindness. Its development can be divided into non-proliferative, with microaneurysms, hard exudates, haemorrhages, and venous abnormalities and proliferative, with neovascularization, pre-retinal or vitreous haemorrhages, and fibrovascular proliferation [112, 113]. Development of glaucoma, retinal detachment, and vision loss may also happen at this stage [114].

A possible role for histamine in this context was postulated when diabetic retinopathy was mainly considered a microvascular complication of endothelial dysfunction with capillary basement membrane (BM) thickening, pericyte and endothelial cell loss, blood-retinal barrier (BRB) breakdown and leakage, acellular capillaries, and neovascularization [115, 116]. Indeed, most of
these vascular effects are consistent with the vasoactive properties of histamine. Antihistamines, such as diphenhydramine (PubChem CID 3100), astemizole (PubChem CID 2247) and ranitidine (PubChem CID 3001055), have been shown to reduce the leakage of retinal vessels in diabetic rats and humans [117, 118], but also to attenuate blood-brain barrier permeability and to ameliorate cerebral blood flow disturbances [119].

In particular, it was reported that histamine specifically affects the zonula occludent (ZO)-1 expression in cultured retinal microvascular endothelial cells [120]. Interestingly, the same authors described a similar inhibitory effect on ZO-1 expression for both high glucose (20mM) and low insulin (10^{-12}M) culturing condition [121]. These data provide a mechanistic interpretation of the ability of histamine to induce a BRB dysfunction in both experimental diabetes and diabetic patients [118, 122, 123], suggesting that the increased histaminergic tone consequent to the diabetic milieu could directly account for the BRB breakdown and leakage vascular, for many years considered pivotal in the pathogenesis of diabetic retinopathy. These effects can be considered at least qualitatively equivalent to those observed for the vascular endothelial growth factor (VEGF) on permeability leakage [124].

The possible involvement of histamine in diabetic retinopathy is still plausible, although not deeply investigated, when, according to the neurodegenerative nature of this disease, the other components of the retina, such as neurons and glial cells are taken into account. It is currently acknowledged that cellular, molecular, and functional changes are evidenced in all the retina cellular compartments [115, 116, 125-127] at an early stage of diabetic retinopathy. Intriguingly, an increase in histamine synthesis was observed within the retinas of diabetic rats [117, 128]. This was due to an over-expression of the HDC enzyme in both the retinal neurons and glia [129]. As mentioned above for plasma, aorta and pancreas, an insulin-histamine loop does exist also within the retina. The histamine overproduction induced by diabetes was decreased by both the HDC inhibitor or insulin administration in experimental diabetes [128].
Therefore, collectively the data in the literature suggest that histamine could at least participate in the neural cell contribution to the diabetes-induced vascular leakage.

3.2.3 Diabetic nephropathy

Diabetic nephropathy is one of the most important causes of chronic kidney disease (CKD), and therefore of end-stage renal disease (ESRD) in Western nations. It has been estimated that the risk of developing CKD is increased by a factor of 12-fold in type 1 diabetes and 6-fold in type 2 diabetes, compared with non-diabetic individuals [130]. About one-third of diabetic patients begin to show persistently high urinary albumin excretion, thence being at high risk to develop in primis diabetic ESRD, but also cardiovascular diseases and premature mortality, even without progression to ESRD [131].

Intriguingly, the first evidence for a possible role of histamine in the development of diabetic nephropathy arose from studies performed in STZ diabetic rats in which histamine levels, consistent with the generalized increase of the amine induced by diabetes, were found to be significantly increased in the kidney [132, 133]. Again, a greater tissue HDC activity without a concomitant decrease in histaminase activity could account for this event [133] especially at the glomerular level which has been identify as the major site of intrarenal histamine synthesis and accumulation [109, 134]. The demonstrated ability of histamine to increase salt and water excretion [135-137], decrease the ultrafiltration coefficient by reducing the total filtration surface area [137], and increase renin release [138] led to the hypothesis of a direct involvement of histamine in regulating the renal microcirculation. For a long period, histamine was claimed to affect the glomerular microcirculation. However, recent evidence suggest and support the hypothesis of direct effects of histamine on glomerular integrity and function, far beyond simply modifying the glomerular hemodynamic microcirculation [139].

At the tubular level, the first evidence of a histamine detrimental effect on tubular integrity and function was already available in the 1960s and 1970s when several reports suggested that mast
cells may be involved in kidney diseases, but as mast cells were not easily detected by routine histochemical staining, they were ignored or forgotten by nephrologists for many years [140]. In the normal kidney, mast cells are constitutively present at a low number. However, their density increases in the renal cortical tubulointerstitium, in the periglomerular and perivascular area, but not in glomeruli, in a variety of human renal diseases including diabetic nephropathy [140-142]. Moreover, mast cells have occasionally been found in the wall of atrophied tubules [142]. In particular, it has been shown that with disease progression, the number and degranulation status of mast cells increased, suggesting that histamine released by mast cells into the tubular interstitium may promote renal inflammation and fibrosis [141, 142]. Indeed, histamine has been reported to promote fibrosis affecting the tissue growth factor (TGF)-β/Smad3/4 axis in the lung [143].

In the past several decades, all the renal effects of histamine were ascribed only to H₃R and H₂R, both identified in the glomeruli [12, 132]. Consistent with results obtained in rats [138], it was found in humans that the H₂R is the subtype present in glomeruli and involved in the cAMP accumulation subsequent to the increasing histamine [144]. Moreover, it has been demonstrated that histamine modulates mesangial cells and glomeruli via H₃R [145]. In the last few years, convergent lines of evidence strongly support the conclusion that all four histamine receptors are present and functional in the human nephron, although with a differential anatomical topology [34]. Notably, among them, both the H₃R and the H₄R have been reported to be profoundly upregulated at the tubular level in STZ treated rats, which also displayed parallel renal damage (mostly again at the tubular level) [33, 146]. These latter data led to a new interest in histamine in kidney (patho)physiology supporting the hypothesis that it could directly and specifically contribute to the onset/progression of diabetic nephropathy.

4 Conclusion

Is it really the time to reconsider the functional contribution of histamine in diabetes? Indeed, although still far from conclusive, different elements point to a clear role of histamine in diabetes
and diabetic complications etiopathogenesis. The evidence is strong in some cases, sometimes independent, but sometimes contradictory; despite this heterogeneity, when viewing the timeline of interest for histamine involvement in this disease (Figure 1) it appears phasic with a clear upturn and renewal in interest in the last couple of years, thanks to the very recent discovery of a direct effect of histamine on glycaemia [13, 16, 17] as well as a profound up-regulation of both H₃R and H₄R in the diabetic animal kidney [33, 146]. As a whole, the revisit of the literature herein clearly shows growing independent lines of evidence for a bidirectional connection between histamine and diabetes (Table I).

<table>
<thead>
<tr>
<th>Table I. The diabetes-histamine loop: the state of the art</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes complication</td>
</tr>
<tr>
<td>------------------------</td>
</tr>
<tr>
<td><strong>macrovascular</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>microvascular</strong></td>
</tr>
<tr>
<td><strong>neuropathy</strong></td>
</tr>
<tr>
<td><strong>peripheral neuropathy</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>autonomic neuropathy</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>retinopathy</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>nephropathy</strong></td>
</tr>
</tbody>
</table>

++ = strongest evidence; + = spare evidence; ? = under investigation/characterization; n.d. = no data
Therefore, a pathophysiological role for this amine cannot be discounted anymore and new studies specifically aimed to assess its function in the onset and progression of the longstanding diabetes complications are strictly warranted. The state of the art on histamine in diabetes is recapitulated in Figure 1.

**Figure 1. Milestones in the story of histamine and diabetes.** Timeline of major events in the history of histamine and its link to diabetes and its complications - 1930s to present day. The phasic interest with the recent upsurge in the last couple of years is depicted.

As reported in Table I, not all the diabetic complications have been provided with the same level of compelling evidence. Many blind spots remain regarding the role of histamine in macrovascular complications where the effect of the amine seems to be mostly related to its general vasoactive properties rather than to a specific function in diabetes. The discrepancies often observed in the literature can be mostly ascribed to the different models adopted as well as to the doses, the administration route and the actual selectivity of the compound used, which could differentially affect the central and peripheral histaminergic system. More notably, the majority of the evidence for histamine involvement in the different diabetes complications arises from studies not directly aimed to assess its role in diabetic disease. This is in particular the case for diabetic peripheral neuropathy where the studies were designed to assess a general role in nociception and/or...
neuropathic pain. Other fields, such as retinopathy, have found using new strategies, effective and specific pharmacological tools that have downgraded the antihistaminergic approach to a supporting role. However, since many of the investigations were prior to the discovery of the newest histamine receptor members H₃R and H₄R, there is scope for new insights in histamine and diabetes, and the opportunity to develop new antihistamine drugs to overcome the paucity of effective therapies.

Conflict of interest none

Acknowledgements This work was funded by the University of Turin (ex60% 2014), World Wide Style Project (WWS; University of Turin/Fondazione CRT) and University of Florence (ex60% 2014). ACR and AP designed the study; AP, EB and IO conducted the literature search and analysis; ACR, AP, IO and PLC wrote or contributed to the writing of the manuscript. All co-authors contributed and have approved the submitted version of the paper.

References


[106] C.G. Irvin, J.A. Dempsey, Role of H1 and H2 receptors in increased small airways resistance in the dog, Respiration physiology 35(2) (1978) 161-76.


H. Gallagher, R.J. Suckling, Diabetic nephropathy - where are we on the journey from pathophysiology to treatment?, Diabetes, obesity & metabolism (2016).


